Protein Kinase Cd (PKCd), a Ca 2+ -independent, phospholipid-dependent serine/threonine kinase, is among the PKC isoforms expressed in mouse epidermis. We reported that FVB/N transgenic mice that overexpress (* eightfold) PKCd protein in basal epidermal cells are resistant to skin tumor formation by the 7,12-dimethylbenz(a)anthracene (DMBA)-initiation and 12-O-tetradecanoylphorbol-13-acetate (TPA)-promotion protocol. However, despite being resistant to skin tumor promotion by TPA, PKCd transgenic mice elicited a 3 ± 4-fold increase in TPA-induced epidermal ODC activity and putrescine levels than their wild-type littermates. PKCd was observed to be the key component of the TPA signal transduction pathways to the induction of mouse epidermal ODC activity. To determine if TPA-induced ODC activity and associated putrescine levels in PKCd transgenic mice contributed to PKCd-mediated suppression of skin tumor promotion by TPA, the irreversible inhibitor of ODC, a-di¯uoromethylornithine (DFMO), was used. PKCd transgenic mice and their wild-type littermates were initiated with 100 nmol DMBA and then promoted twice weekly with 5 nmol TPA. The experimental group was given 0.5% DFMO in their drinking water, while the control group was given tap water. After 25 weeks, the number of papillomas (42 mm) per mouse was counted. The DFMO treatment did not aect the skin tumor multiplicity of PKCd transgenic mice. These results indicate that PKCdinduced ODC activity is not involved in PKCd-mediated tumor suppression. Thus, the signaling pathways via PKCd to epidermal ODC induction and skin tumor suppression appear to be independent.
Introduction
Ornithine decarboxylase (ODC), which decarboxylates ornithine to form putrescine, is the key enzyme in mammalian polyamine biosynthesis (Jackson et al., 2000; Pegg, 1986) . Polyamines play important roles in normal cell proliferation and dierentiation as well as in malignant transformation (Igarashi and Kashiwagi, 2000; Hobbs and Gilmour, 2000) . TPA-induced ODC and the resultant accumulation of putrescine have been shown to be essential in mouse skin tumor promotion by TPA (Gilmour et al., 1987; O'Brien et al., 1997) . Mouse skin tumor promoters, either protein kinase C (PKC) activators, such as TPA, or non-PKC activators, such as okadaic acid, induce mouse epidermal ODC activity (O'Brien et al., 1997; Suganuma et al., 1988) . High levels of ODC and polyamines are found in mouse skin papillomas (O'Brien et al., 1997; Suganuma et al., 1988; Koza et al., 1991) . Overexpression of a constitutively active ODC molecule in the epidermis leads to tumor formation after initiation alone, in the absence of an exogenous promoting agent (O'Brien et al., 1997) . Furthermore, DFMO, a suicide inhibitor of ODC, which inhibits TPA-induced ODC activity, precludes accumulation of putrescine and inhibits skin tumor promotion by TPA (Takigawa et al., 1982; Weeks et al., 1982) . Evidence also exists which indicates that TPA-induced ODC activity does not correlate with skin tumor promotion susceptibility with dierent strains of mice (DiGiovanni et al., 1984; Fischer et al., 1988; Hirabayashi et al., 1988; Imamoto et al., 1992) . This suggests that TPA-induced ODC activity is necessary for tumor promotion but not sucient within the context of dierent mouse strains. The loss of ODC activity may limit or inhibit papilloma development, while constitutive ODC activity may be sucient for tumor promotion after treatment with DMBA on certain genetic backgrounds.
PKC is a major intracellular receptor for TPA (Driedger and Blumberg, 1980; Ashendel et al., 1983; Kikkawa et al., 1983; Verma, 1988 Verma, , 1995 Niedel et al., 1983; Nishizuka, 1995) . PKC represents a family of 11 related serine/threonine protein kinases (Coussens et al., 1986; Mochly-Rosen and Kauvar, 1998; Nishizuka, 1995; Mellor and Parker, 1998; Newton, 1997) . TPA can directly activate nine of these PKC isoforms (Nishizuka, 1995; Coussens et al., 1986) . To determine Figure 1 Mouse skin tumor promotion susceptibility of T7-PKCd mice. Wild-type and T7-PKCd mice were initiated with a single 100 nmol dose of DMBA and promoted twice weekly with 5 nmol of TPA. In this experiment, both T7-PKCd males and females and their wild-type littermates were treated in parallel (a ± c: males; d ± f: females). There were 20 mice per treatment group. The tumor incidence and multiplicity were determined during 25 weeks of tumor promotion. The error bars indicate the s.e.m. of the papilloma multiplicity for each papilloma count. Carcinoma incidence refers the percentage of mice with at least one carcinoma. (a and d) Papillomas per mouse; P value 50.001 at week 25. (b and e:) Per cent mice with at least one papilloma. (c and f) Per cent mice with at least one carcinoma; P value 50.001 at week 25 the in vivo functional speci®city of PKCa, -d, and -e in TPA activated PKC signals to ODC induction and skin tumor multiplicity, we generated transgenic mice that expressed T7-epitope-tagged PKCa, -d, or -e in their epidermis. The expression of individual PKC isoforms was directed to the basal cells of the epidermis using a human cytokeratin 14 (K14) promoter (Reddig et al., 1999 (Reddig et al., , 2000 Jansen et al., 2001a) . Overexpression of PKCa did not aect the induction of skin tumors elicited by the initiation (DMBA) ± promotion (TPA) protocol (Jansen et al., 2001a; Wang and Smart, 1999) . However, the overexpression of PKCd suppressed the formation of both skin papillomas and carcinomas (Reddig et al., 1999) while PKCe transgenic mice developed papilloma-independent metastatic squamous cell carcinomas (Reddig et al., 2000; Jansen et al., 2001b) . Interestingly, despite dierent skin tumor promotion susceptibilities of PKCa, PKCd, and PKCe transgenic mice, PKCd and PKCe, but not PKCa, overexpressing transgenic mice super-induced epidermal ODC activity compared to wild-type littermates after TPA treatment (Jansen et al., 2001a) . In this communication, we determined whether TPA-caused overinduction of ODC activity is linked to the skin tumor suppression in PKCd transgenic mice. We present data indicating that inhibition of TPA-induced ODC activity in PKCd transgenic mice did not alter their skin tumor promotion susceptibility.
Results
PKCd overexpression results in increased sensitivity to ODC induction but leads to inhibition of skin tumor promotion by TPA
The results of skin tumor promotion susceptibility of PKCd transgenic mice are summarized in Figure 1 . In this experiment, PKCd transgenic mice and their wildtype littermates were initiated by application of a single 100 nmol dose of DMBA and then treated twiceweekly with 5 nmol TPA in 0.2 ml acetone. Both the male (Figure 1a ± c) and the female (Figure 1d ± f) PKCd transgenic mice were resistant to the induction of both skin papillomas and carcinomas throughout the 25 week period of the tumor induction experiment. As compared to the wild-type littermates, the papilloma multiplicity and carcinoma incidence were signi®-cantly (P50.001) suppressed in both male and female PKCd transgenic mice. These results (Figure 1 ) are in accordance to our previous ®ndings (Reddig et al., 1999) .
We further determined changes in PKCd activity during skin tumor promotion by TPA. In this experiment (Figure 2a ), PKCd enzyme activity was determined by the immunocomplex kinase assay from mouse epidermal extract at 3, 6, 24, 48, 72 or 96 h after a single TPA application to skin. In the wild-type mice, TPA treatment led to a decrease in PKCd activity by 6 h. In contrast, PKCd activity in the PKCd transgenic mice remained unaltered for 24 h after TPA treatment and then was increased at 48 and 72 h before returning to near basal levels at 96 h after TPA treatment. To examine PKCd activity after multiple TPA treatments, protein was collected from acetone-and TPA-treated uninvolved skin, as well as papillomas of both PKCd transgenic mice and their wild-type littermates after 24 weeks of tumor promotion ( Figure  2b ). In the wild-type TPA-treated epidermis, there was a slight decrease in PKCd activity compared to the acetone treated skin. In the wild-type papilloma, PKCd activity was completely lost. TPA-treated epidermis from PKCd transgenic mice elicited an increase in PKCd activity. Most notably, the papillomas that did form in PKCd transgenic mice were dramatically reduced in size and had increased PKCd activity.
The response of PKCd transgenic mice to ODC induction by TPA is illustrated in Figure 3a ± c. In these experiments, the eects of either single or multiple TPA applications to skin on the induction of ODC activity and polyamine levels were compared between PKCd transgenic mice and their wild-type littermates. The results are illustrated in Figure 3a ± c. The experimental results shown in Figure 3a ,b and c were performed with dierent groups of mice. A TPA dose-response study indicated that at a 5 nmol dose TPA induced 3 ± 4-fold more ODC activity in PKCd transgenic mice than wild-type mice (Figure 3a) . Similar results were observed with TPA-induced putrescine levels (Figure 3b ).
The eects of chronic applications of TPA to the DMBA-initiated skin on ODC induction in PKCd transgenic mice are shown in Figure 3c . In this experiment, PKCd transgenic mice and their wild-type littermates were initiated by single application of 100 nmol DMBA and then treated twice weekly with 5 nmol of TPA. The induction of ODC activity was determined 5 h after the last (17th) TPA application. Application of TPA either at a 5 or 10 nmol dose resulted in the induction of ODC activity in PKCd transgenic mice about 4 ± 5-fold more than the wildtype mice (Figure 3c) . Furthermore, the level of ODC mRNA in the T7-PKCd mice was also elevated fourfold at the 5 nmol TPA dose as compared to the wild-type controls (Figure 4 ). were applied only once in 0.2 ml acetone to the shaved backs of the indicated mice. Epidermal ODC activity and polyamine levels were determined at 4.5 h and 7 h after single TPA treatment, respectively. In a separate experiment (c), PKCd transgenic mice and their wild-type littermates were initiated by applying 100 nmol of DMBA to their shaved backs. One week after initiation, 5 nmol of TPA was applied to skin twice weekly for 8 weeks (16 TPA applications). At the 17th TPA treatment, 5 or 10 nmol of TPA was applied and epidermal ODC activity was determined 5 h after TPA treatment. Each value is the mean+s.e. of duplicate determinations of ODC activity of soluble epidermal extract from three mice. *Signi®cantly dierent (P50.001) from their wild-type littermates
The role of PKCd in TPA-induced ODC activity was further evaluated using PKCd knockout (KO) mice. PKCd KO mice were generated with the LacZNeo cassette ( Figure 5a ) by interrupting the initiating codon. The genetic background used was 129/Ola and C57BL/6 strains. Mice were screened using Southern blot and PCR analysis on genomic DNA ( Figure 5b ). Western analysis of extract from the dorsal skin indicated a lack of PKCd protein in the PKCd KO mouse epidermis, while the heterozygote mice contained less protein than wild-type mice ( Figure  5b ). The possibility was explored that loss of PKCd may result in compensatory alterations in the level of expression of other PKC isoforms ( Figure 5c ). The levels of expression of various PKC isoforms in epidermal extracts from untreated wild-type mice and mice heterozygous and homozygous null at the PKCd allele were determined by immmunoblot analysis. Using actin as an equal loading control, it appears that none of the other PKC isoforms was either lost or dramatically elevated.
To determine the role of PKCd in TPA-induced ODC activity, keratinocytes from PKCd KO mice and their wild-type littermates were prepared. The keratinocytes were treated with 5 or 10 nM of TPA at 18 h after plating and ODC activity was determined 6 h after treatment. The results are depicted in Figure 6 . TPA-induced ODC activity in primary keratinocytes isolated from PKCd KO mice was suppressed by about 80% as compared to the keratinocytes from their wild type littermates.
TPA-induced hyperplasia and expression of cell cycle regulatory proteins in PKCd transgenic mice
Though diverse in structure and function, a common characteristic of tumor promoters, including phorbol esters and okadaic acid, is the ability to induce hyperplasia (Argyris, 1985) . The phorbol ester tumor promoter TPA is especially adept at enhancing epidermal growth. Repeated treatment of the skin with TPA induces sustained hyperplasia (Sisskin et al., 1982; Aldaz et al., 1985) . We determined whether overexpression of PKCd altered TPA-induced hyperplasia (Figure 7) . In this experiment, the shaved dorsal skin of T7-PKCd transgenic and wild-type mice were treated with a single TPA dose (5 nmol) and at 18 or 24 h after treatment, the dorsal skin was removed and ®xed in 10% formalin for H & E staining. Both PKCd transgenic and wild-type mice displayed an equal degree of hyperplasia ( Figure 7 , Table 1 ). Furthermore, PKCd transgenic mice and wild-type littermates treated with a single 5 nmol dose of TPA at 0, 3, 6, 9, 12 and 18 h showed no dramatic change in the cell cycle regulators such as cyclin A, D1, D2, D3, E, cdk4, cdk6, p21, p27, or PCNA (data not shown).
The ODC inhibitor a-difluoromethylornithine (DFMO) did not affect skin tumor promotion susceptibility of PKCd transgenic mice TPA-induced increased levels of ODC have been tightly correlated with mouse skin tumor promotion (Gilmour et al., 1987; O'Brien et al., 1997) . ODC levels peak at both the G1/S and the G2/M boundaries and are believed to play a both a functional and structural role in cellular proliferation (Jackson et al., 2000; Pegg, 1986; Igarashi and Kashiwagi, 2000) . We were intrigued to ®nd that overexpression of PKCd in the mouse epidermis not only suppressed the formation of papillomas but also super-induced ODC activity. To determine if the induction of ODC in PKCd mice plays a role in tumor suppression, we compared the eects of inhibition of TPA-induced ODC by DFMO on skin tumor formation in PKCd transgenic mice and their wild-type littermates. In this experiment (Figure 8 ), the mice were initiated with 100 nmol DMBA and then promoted twice weekly with 5 nmol TPA for 25 weeks. The control mice were given tap water while the experimental mice were given 0.5% DFMO in their Figure 4 Eect of TPA on the induction of steady-state levels of epidermal ODC mRNA in wild-type and T7-PKCd transgenic mice. Acetone (0.2 ml) or 5 nmol TPA in 0.2 ml acetone was applied once to the shaved backs of mice. At 4 h after treatment, mice were killed and the skin was excised and subcutaneous fat was removed. Total RNA from the pulverized skin was isolated and analysed for ODC mRNA by Northern blot analysis. For the Northern blot analysis, RNA (15 mg) was fractionated by electrophoresis in a denaturing formaldehyde:agarose gel and transferred to GeneScreen. RNA bands containing ODC mRNA were detected and quantitated by radioactive probes from pODC10/2H or 18S cDNA fragments labeled with [a-32 P]dCTP as described under Material and methods drinking water. DFMO at 0.5% level in tap water was found to inhibit more than 90% TPA-induced ODC activity in both PKCd transgenic and their wild-type littermates (data not shown). The results of the eects of DFMO on skin tumor promotion by TPA are shown in Figure 8 . The wild-type mice on tap water exhibited a tumor burden on average of 9.5+1.45 papillomas per mouse, while the tumor burden in wildtype mice on DFMO water was decreased to an average of 2.7+0.46 papillomas per mouse. The PKCd transgenic mice on tap water had a tumor burden of 2.8+0.6 papillomas per mouse while the DFMOtreated mice had 2.74+0.37 papillomas per mouse. The weights of the mice throughout the experiment were unaected by DFMO treatment.
Discussion
PKCd is a ubiquitously expressed Ca 2+ -unresponsive TPA/diacylglycerol-activated PKC isozyme (Coussens et al., 1986; Mochly-Rosen and Kauvar, 1998; Nishizuka, 1995; Mellor and Parker, 1998; Newton, 1997) . PKCd occupies a central position in a cell's signaling network that regulates a wide variety of cellular processes, which include suppression of cell proliferation and transformation, induction of apoptosis and dierentiation (Coussens et al., 1986; MochlyRosen and Kauvar, 1998; Nishizuka, 1995; Mellor and Parker, 1998; Newton, 1997) . We found PKCd to be a potent suppressor of the induction of both papillomas and carcinomas in intact mouse skin in vivo. The mechanism by which PKCd overexpression results in inhibition of skin tumor formation is yet unclear. TPAinduced ODC activity has been shown to be correlated with mouse skin tumor promotion. (Gilmour et al., 1987; O'Brien et al., 1997) . Such a correlation was not observed in PKCd transgenic mice. On the contrary, PKCd overexpression suppressed TPA-induced tumor formation while it super-induced ODC activity ( Figure  3 (ii) PCR analysis. A primer set (primer A and B) was designed to amplify a 275-basepair fragment of exon one to test for the wild-type allele. Primers C and B were used to test for the mutant allele (700 bp). (iii) Western analysis. The untreated epidermis was removed from PKCd wild-type, heterozygous, or knockout mice and homogenized, immunoprecipitated, and fractionated by SDS ± PAGE. The protein was transferred to PVDF membrane and immunoblotted with a rabbit anti-PKCd polyclonal antibody. (c) PKC isoform expression in PKCd KO mice. Untreated epidermis was removed from PKCd wild-type (Wt), heterozygous (Ht), or knockout (KO) mice and homogenized in IP lysis buer. One hundred mg of whole cell extract was fractionated by SDS ± PAGE and immunoblotted for individual PKC isoforms. The actin level was used as a control for gel loading variations hanced the reporter gene activity (Tseng et al., 1994) and (2) inhibition of PKCd activity by use of a dominant negative PKCd inhibited the induction of ODC activity (Otieno and Kensler, 2000) . The results presented in Figure 3 clearly indicate that the transgenic mice, which overexpress PKCd in their epidermis, are more responsive to TPA for the induction of ODC activity than their wild-type littermates. Overinduction of ODC was observed either after a single or repeated TPA application to skin (Figure 3) . It is noteworthy that the levels of both epidermal PKCd protein, and PKCd activity, remained increased which correlated with the induction of ODC activity in PKCd transgenic mice (Figure 2 ). These results (Figures 2 and 3) together with suppressed response of keratinocytes from PKCd KO mice to ODC induction by TPA (Figure 6) indicate that PKCd activity level determines the degree of induction of ODC activity by TPA. In this context, the report by Otieno and Kensler (2000) is also notable. In their ®ndings, oxidant-induced ODC activity in murine papilloma cells was completely inhibited by over expression of dominant-negative PKCd. These results further implicate the direct involvement of PKCd in the regulation of ODC gene expression.
DFMO, which inhibits TPA-induced ODC activity (Verma, 1992) , did not alter the response of PKCd transgenic mice to skin tumor promotion by TPA. If ODC had been downstream of PKCd signals to skin tumor suppression, then inhibition of ODC activity by DFMO treatment could have reversed the tumor susceptibility of PKCd transgenic mice to their wildtype littermates. The lack of eect of DFMO treatment on the sensitivity of PKCd transgenic mice to skin tumor promotion by TPA indicates that the PKCdmediated signals to ODC induction and skin tumor Figure 6 TPA-induced ODC activity in keratinocytes from PKCd KO mice. Keratinocytes were prepared, plated in triplicate and ODC activity determined from PKCd KO and wild-type mice as described under the Materials and methods Figure 7 A comparison of TPA-induced epidermal hyperplasia in PKCd transgenic mice and their wild-type littermates. Wildtype and PKCd transgenic mice were treated once with 5 nmol of TPA. Mice were sacri®ced at the indicated times after treatment. The dorsal skin was excised and was ®xed in 10% neutral buered formalin, embedded in paran, and sections (4 mm) was stained with hematoxylin and eosin as described in the Materials and methods Figure 8 Lack of eect of DFMO on skin tumor promotion in PKCd transgenic mice. PKCd transgenic mice and their wild-type littermates were initiated with a single 100 nmol dose of DMBA and promoted twice weekly with 5 nmol of TPA. DFMO (0.5%) was given in the drinking water. The control group was given tap water. There were 20 mice per group. Shown are the papillomas/ mouse at 25 weeks of tumor promotion. Tumor response of PKCd transgenic mice either on tap water or 0.5% DFMO was not signi®cantly dierent (P40.1) suppression are not on the same linear pathway. This relationship between TPA-induced ODC activity and skin tumor multiplicity in PKCd transgenic mice diered from the tight correlation between these two measures of TPA response observed in CD-1 mice (Gilmour et al., 1987; O'Brien et al., 1997; Suganuma et al., 1988; Koza et al., 1991; Takigawa et al., 1982; Weeks et al., 1982) . Also, comparisons of the TPA induction of ODC in inbred strains of mice (C57BL/6, SENCAR, and DBA/2) with varying levels of sensitivity to tumor promotion by TPA demonstrated a dissociation of these responses. The C57BL/6 strain, which is resistant to TPA tumor promotion, showed greater induction of ODC activity in response to TPA than the SENCAR or DBA/2 strains, which are more sensitive to tumor promotion (DiGiovanni et al., 1984; Fischer et al., 1988; Hirabayashi et al., 1988; Imamoto et al., 1992) . This again suggests that induction of ODC is not sucient. The lack of correlation between TPA-induced ODC activity and skin tumor multiplicity in PKCd transgenic mice can be explained as follows: (1) ODC is the key enzyme in the biosynthesis of mammalian polyamines, which regulate a wide-variety of cellular processes (Pegg, 1986; Igarashi and Kashiwagi, 2000) . The level of polyamines is regulated at the levels of biosynthesis, interconversion and degradation (Pegg, 1986; Igarashi and Kashiwagi, 2000) . Polyamines spermidine and spermine are acetylated and then excreted to maintain the intracellular polyamine pool. Although ODC is superinduced in PKCd transgenic mice, it is likely that because of interconversion, degradation and excretion that a critical level of polyamines and/or spermidine/spermine ratio essential to favor tumor promotion is never achieved. (2) PKCd may activate a signaling pathway, independent of one leading to ODC induction, which may interfere with polyamine speci®c signals to skin tumor promotion by TPA.
Evidence also indicates that elevation of polyamine levels increases cellular apoptosis (Hu and Pegg, 1997; Zhan et al., 1997) . It is likely that elevated putrescine levels in PKCd transgenic mice may be involved in the induction of apoptosis. PKCd has been implicated in the cell death pathways. Reyland et al. (1999) reported that etoposides, a topoisomerase inhibitor, activates caspases which induce the cleavage of PKCd into its catalytic fragments and results in apoptosis. Emoto et al. (1995) have shown that various apoptosis-inducing stimuli such as TNFa, ARA-C, anti-Fas antibody and radiation result in the proteolytic cleavage of PKCd (Emoto et al., 1995 Ghayur et al., 1996) . Similarly, ultraviolet radiation or ceramides, which activate caspases, result in the cleavage of PKCd and apoptosis (Denning et al., 1998; Sawai et al., 1997) .
The most frequently identi®ed genetic alteration after initiation is the activation of the Hras locus in mice (Balmain et al., 1984) . The simplest explanation for how PKCd overexpression suppresses tumor formation may be that PKCd selectively induces apoptosis of initiated cells. This may be achieved by cross-talk between ras and PKCd signaling pathways. A majority of the DMBA-initiated cells have mutations in H-ras genes. Mutations lock ras in the active GTP-bound state (Vojtek and Der, 1998) . Also, ras-induced cell survival and cell death are mediated by a distinct cascade of kinases (Vojtek and Der, 1998) . It is likely that PKCd-mediated signals may block the ras-induced cell survival signal and activate the cell death signal (Rajesh et al., 1999) . In this way, PKCd overexpression may selectively induce apoptosis of DMBA-initiated cells.
The inhibition of TPA-induced papillomas in T7-PKCd mice is probably controlled at the level of tumor promotion. Unlike initiation, tumor promotion occurs slowly, reversibly, and is a rate-limiting event in tumor development (Verma and Boutwell, 1980; Boutwell, 1974; Furstenberger et al., 1985; Slaga et al., 1996) . The over expression of PKCd may either decrease the growth kinetics of the initiated cells or inhibit their clonal expansion until another genetic hit occurs, releasing initiated cells from PKCd inhibition. Many studies have shown that overexpression of PKCd can cause growth inhibition. These studies include: PKCd overexpression in capillary endothelial cells (Harrington et al., 1997), NIH3T3 ®broblasts (Mischak et al., 1993) , smooth muscle cells (Fukumoto et al., 1997) and CHO cells (Watanabe et al., 1992) . A clue to the mechanism of PKCd-mediated growth arrest was ®rst elucidated by experiments performed by Fukomoto et al. (1997) . In this report they observed, in vitro, that overexpression of PKCd in vascular smooth muscle cells resulted in reduction of G1 cyclin (cyclin D1 and cyclin E) levels. Furthermore, their studies revealed that the tumor suppressor Rb was underphosphorylated and thus, able to sequester the E2F family of transcription factors. All of these events may play a role in inhibiting the G1-S transition and thus, slow cellular division.
In summary, we found that PKCd overexpression suppresses skin tumor formation while over induces epidermal ODC. PKCd activation appears to be an initial signal in TPA-induced ODC gene transcription and epidermal ODC activity. Inhibition of ODC activity using the suicide inhibitor, DFMO, reduced epidermal ODC activity by 90% but had no eect tumor formation in PKCd transgenic mice. We therefore conclude that signals mediated by PKCd to the induction of ODC and to skin tumor suppression are independent.
Materials and methods

Materials
TPA was purchased from Alexis Corporation, San Diego, CA, USA. DMBA was purchased from Aldrich Chemical Company, Inc., Milwaukee, WI, USA. The Bio-Rad Protein Assay reagents were purchased from Bio-Rad Laboratories, Hercules, CA, USA. All other chemicals were purchased from Sigma, St. Louis, MO, USA. FVB/NTacBR mice (FVB/ N), 7 ± 9 weeks of age, were purchased from Taconic, Germantown, NY, USA.
Mice
The mice were housed in groups of 3 ± 4 in plastic-bottom cages in light, humidity, and temperature controlled rooms; food and water were available ad libitum. The animals were kept in a normal rhythm of 12-h light and 12-h dark periods. Transgenic mice were maintained by mating transgenic mice with wild-type FVB/N mice. The PKCd knockout mice were generated and provided by Dr Michael Leitges (Max-Planck Institute for Experimental Endocrinology, Feodor-LynenStr.7, 30625 Hanover, Germany). Brie¯y, the ES cell line used for targeting was E14 from the mouse strain 129/Ola. The ES cells from 129/Ola were introduced into the blastocyte of C57BL/6. The germline chimeras were identi®ed by the presence of agouti coat color in the F1 progeny. Homologous recombination at the locus was con®rmed by Southern Blot analysis using tail genomic DNA.
Tumor induction experiment
At 7 ± 9 weeks of age, the dorsal skins of the mice were shaved 3 ± 4 days before treatment, and those mice in the resting phase of their hair cycle were used for experimentation. The solutions of TPA and DMBA were prepared in acetone and were applied to the shaved backs of individual mice in a volume of 0.2 ml. Mouse skin tumors were induced by the initiation-promotion regimen (Verma and Boutwell, 1980) . For mouse skin tumor initiation, a single 100 nmol dose of DMBA in 0.2 ml of acetone was applied topically to the shaved backs of mice. Two weeks after initiation, TPA in 0.2 ml acetone was applied twice weekly to skin for the duration of the experiment. The papilloma multiplicity was observed every other week. Carcinomas were recorded grossly as downward-invading lesions, which were con®rmed histologically.
Assay of ODC activity
For assay of ODC activity from mouse epidermis, mice were sacri®ced by cervical dislocation at the appropriate time after treatment and the epidermis from individual mice was separated from the dermis by a brief heat treatment (578C for 30 s). Epidermal preparations were homogenized in 50 mM Tris-HCl buer (pH 7.2) containing 0.1 mM pyridoxal phosphate, 1 mM DTT, and 0.1 mM EDTA. For assay of ODC activity from mouse keratinocytes, keratinocytes were treated as indicated 18 h after plating. Cells were harvested in the above buer and epidermal extract was prepared as described before (Jansen et al., 2001; Verma et al., 1986) . The epidermal extracts were centrifuged at 30 000 g for 15 min to give a soluble supernatant. Soluble epidermal ODC activity was determined by measuring the release of 14 CO 2 (Jansen et al., 2001; Verma et al., 1986) . The protein content in the soluble epidermal extracts was determined by the BioRad Protein Assay (Hercules, CA, USA).
Northern blot analysis
Total RNA was extracted with Trizol reagent as described by the manufacturer. Total RNA (15 mg) was fractionated on a denaturing formaldehyde-agarose gel. The RNA was transferred to GeneScreen using Stratagene's Posiblot 30 ± 30 Pressure Blotter (La Jolla, CA, USA) and UV crosslinked. pODC10/2H or 18S cDNA fragments were labeled with [a- 32 P]dCTP with Boehringer Mannheim's Random Primed DNA Labeling Kit (Indianapolis, IN, USA) and used as probes for ODC and 18S RNA. Signals were visualized by autoradiography and quantitated by a PhosphoImager with ImageQuant (Molecular Dynamics, Sunnyvale CA, USA).
Immunoblotting of PKC isoforms
Mice were shaved and depilated before experimentation. The mouse skin was excised and scraped to remove the subcutaneous fat. The epidermis was removed and homogenized in IP lysis buer (50 mM HEPES, pH 7.5, 150 mM NaCl, 10% glycerol, 1% Triton X-100, 1.5 mM MgCl 2 , 10 mg/ml aprotinin, 10 mg/ml leupeptin, 1 mM PMSF, 200 mM Na 3 VO 4 , 200 mM NaF, and 1 mM EGTA). The homogenate was centrifuged at 14 000 g for 30 min at 48C. One hundred mg of whole cell lysate was fractionated on a 7.5% SDSpolylacrylamide gel. The proteins were transferred to 0.45 mm Hybond-P PVDF transfer membrane (Amersham). The membrane was then incubated with the appropriate primary and secondary antibodies, and the detection signal was developed with Amersham's ECL reagent. Rabbit polyclonal antibodies to PKC a, bI, bII, d, e, Z, m, and z, were used at a 1 : 1000 dilution to detect the respective PKC isoforms.
PKC Immunocomplex kinase assay
PKCd activity was determined using PKC immunocomplex kinase assay kit (Reddig et al., 1999) . The dorsal skin of mice was shaved and depilated before experimentation. The mice were euthanized, the dorsal skin was removed, and the epidermis was scraped o on ice with a razor blade. The epidermis from 2 ± 3 mice were pooled and placed in 0.5 ml IP lysis buer, homogenized in a glass te¯on tissue homogenizer, and agitated for 30 min at 48C. After centrifugation for 15 min at 14 000 r.p.m., the supernatant was used for immunoprecipitation. The lysate was preabsorbed with 5 ml of protein A/G agarose for 30 min at 48C. Five mg of monoclonal anti-PKCd (Transduction Laboratories) and 10 ml of protein A/G agarose was added to the lysate and the volume of the lysate was adjusted to 1 ml with lysis buer. The mixture was incubated for 2 ± 4 h at 48C with agitation. The immunoprecipitate was pelleted at 14 000 r.p.m. in a microcentrifuge, washed, and resuspended in 300 ml assay buer (50 mM Tris-HCl pH 7.4, 5 mM EDTA pH 8.0, 10 mM EGTA pH 7.9, 0.3% b-mercaptoethanol, 5 mg/ml aprotinin, 5 mg/ml leupeptin, and 50 mg/ml PMSF). Twenty-®ve ml of the immunoprecipitate was assayed in kinase buer containing 50 mM Tris-HCl pH 7.4, 8 mM MgCl 2 , 0.136 mM ATP, 0.2 mCi [g-32 P]ATP, 100 mM EGFR peptide (ERKRTLRRL), 3 mM DTT, 34 mg/ml of Laphosphatidyl-L-serine, and 3 mg/ml TPA and 1 mM EGTA. The reaction was incubated at 378C for 15 min, stopped with 10 ml of 300 mM H 3 PO 4 , spotted onto ®lter discs, washed with 75 mM H 3 PO 4 , and counted.
Quantitation of hyperplasia
For analysis of hyperplasia, the shaved dorsal skin of T7-PKCd transgenic mice and their wild-type littermates were treated once with 5 nmol TPA in 0.2 ml acetone or acetone alone. At the indicated times after treatment, the dorsal skin was removed, ®xed in 10% formalin and embedded in paran. Sections (4 mm) were cut for hematoxylin and eosin staining. The area of excision was consistent among all mice. Hyperplasia analysis was performed by randomly counting the cells in each epidermal layer. Fifteen randomly selected areas were counted per mouse. Two mice were used for each group, for a total of 30 areas.
Statistical analysis
Data was analysed by Wilcoxon rank sum test using the MSTAT computer program (provided by Dr Norman Drinkwater, Madison, WI, USA). Two-sided P values were calculated for papilloma multiplicity and hyperplasia by Wilcoxon rank sum test. Two-sided P values were calculated using Fisher's exact test to compare tumor incidence. Twosided P values were calculated using Student's t-test for ODC activity.
Abbreviations TPA, 12-O-tetradecanoylphorbol-13-acetate; PKC, protein kinase C; DMBA, 7, anthracine; DFMO, a-di¯uoromethylornithine; ODC, ornithine decarboxylase
